Earlier this year, Bristol Myers Squibb (BMS), the manufacturer of abatacept (Orencia®), imposed supply restrictions on this biologic medication due to global supply chain challenges. Abatacept is commonly used to treat certain forms of autoimmune arthritis, and during the shortage, many patients were required to either switch to alternative treatments or extend the time between their doses to manage their condition.

Fortunately, BMS has recently announced an improvement in the supply of abatacept.

Update: August 01, 2024. 

As of August 1, 2024, Bristol Myers Squibb (BMS) has announced the cessation of the Orencia® Stock Hypercare Plan (OSHP) due to an improved supply situation for Orencia® (abatacept). This update brings significant changes for patients and healthcare providers:

• Improved Supply: BMS has received approximately 16 weeks’ worth of abatacept ClickJect autoinjector ahead of schedule, which is expected to meet normal demand.
• OSHP Form No Longer Required: From August 1, prescribers will no longer need to complete an OSHP form for patients requiring abatacept.
• Patient Switching: Patients may be switched back to abatacept if clinically appropriate.
• Dosing Adjustments: Patients whose dosing intervals were increased during the shortage may return to their previous dose if clinically appropriate.
• New Patients: Both subcutaneous (SC) and intravenous (IV) abatacept can now be prescribed to new patients.
• Serious Scarcity Substitution Instrument (SSSI): The SSSI will remain in effect until October 31, 2024. This allows pharmacists to substitute the abatacept ClickJect autoinjector for the pre-filled syringe without a new prescription.
• Pre-filled Syringe Supply: The next shipment of abatacept pre-filled syringes is expected in late September.

It’s important to note that while the supply situation has improved, patients should consult with their healthcare providers regarding any changes to their treatment regimen. BMS is communicating these updates to relevant pharmaceutical organisations to ensure smooth implementation of these changes.